{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:23:23Z","timestamp":1792592603802,"version":"4.5.0"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2020,12,1]]},"DOI":"10.1001\/jamapsychiatry.2020.2076","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T16:10:57Z","timestamp":1594829457000},"page":"1217","source":"Crossref","is-referenced-by-count":187,"title":["Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia"],"prefix":"10.1001","volume":"77","author":[{"given":"John M.","family":"Kane","sequence":"first","affiliation":[{"name":"Departments of Psychiatry and Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York"},{"name":"The Feinstein Institutes for Medical Research, Institute of Behavioral Science, Northwell Health, Manhasset, New York"},{"name":"The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina R.","family":"Schooler","sequence":"additional","affiliation":[{"name":"SUNY Downstate Health Sciences University, Brooklyn, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Marcy","sequence":"additional","affiliation":[{"name":"Vanguard Research Group, Glen Oaks, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[{"name":"Departments of Psychiatry and Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York"},{"name":"The Feinstein Institutes for Medical Research, Institute of Behavioral Science, Northwell Health, Manhasset, New York"},{"name":"The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, New York"},{"name":"Charit\u00e9 Universit\u00e4tsmedizin Berlin, Department of Child and Adolescent Psychiatry, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Achtyes","sequence":"additional","affiliation":[{"name":"Cherry Health, Grand Rapids, Michigan"},{"name":"Michigan State University College of Human Medicine, Grand Rapids"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Gibbons","sequence":"additional","affiliation":[{"name":"University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delbert G.","family":"Robinson","sequence":"additional","affiliation":[{"name":"Departments of Psychiatry and Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York"},{"name":"The Feinstein Institutes for Medical Research, Institute of Behavioral Science, Northwell Health, Manhasset, New York"},{"name":"The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9831","key":"yoi200043r1","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"yoi200043r2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/wps.v19.1","article-title":"20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20).","volume":"19","author":"Taipale","year":"2020","journal-title":"World Psychiatry"},{"issue":"13","key":"yoi200043r3","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1017\/S0033291717000873","article-title":"Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis.","volume":"47","author":"Vermeulen","year":"2017","journal-title":"Psychol Med"},{"issue":"3","key":"yoi200043r4","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/schbul\/sbu164","article-title":"Antipsychotic treatment and mortality in schizophrenia.","volume":"41","author":"Torniainen","year":"2015","journal-title":"Schizophr Bull"},{"issue":"8","key":"yoi200043r5","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1176\/appi.ajp.2018.17091001","article-title":"20-Year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia.","volume":"175","author":"Tiihonen","year":"2018","journal-title":"Am J Psychiatry"},{"issue":"2","key":"yoi200043r6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/wps.v17.2","article-title":"What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?","volume":"17","author":"Correll","year":"2018","journal-title":"World Psychiatry"},{"issue":"6","key":"yoi200043r7","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41386-018-0278-3","article-title":"Does relapse contribute to treatment resistance? antipsychotic response in first- vs. second-episode schizophrenia.","volume":"44","author":"Takeuchi","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"yoi200043r8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1176\/appi.ajp.2011.10081224","article-title":"A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.","volume":"168","author":"Tiihonen","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"3","key":"yoi200043r9","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/wps.v12.3","article-title":"Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies.","volume":"12","author":"Kane","year":"2013","journal-title":"World Psychiatry"},{"key":"yoi200043r10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.15032su1","article-title":"The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence.","volume":"77","author":"Correll","year":"2016","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"yoi200043r11","doi-asserted-by":"publisher","first-page":"23S","DOI":"10.1177\/088740341305805s04","article-title":"A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II-physician perspectives.","volume":"58","author":"Iyer","year":"2013","journal-title":"Can J Psychiatry"},{"issue":"1-3","key":"yoi200043r12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.schres.2015.08.015","article-title":"Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia.","volume":"169","author":"Schreiner","year":"2015","journal-title":"Schizophr Res"},{"issue":"8","key":"yoi200043r13","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1001\/jamapsychiatry.2015.0270","article-title":"Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. a randomized clinical trial.","volume":"72","author":"Subotnik","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"yoi200043r14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3371\/CSRP.MACH.061213","article-title":"An exploratory, open-label, randomized trial comparing risperidone long-acting injectable with oral antipsychotic medication in the treatment of early psychosis.","volume":"9","author":"Malla","year":"2016","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"4","key":"yoi200043r15","first-page":"25","article-title":"Three-year naturalistic study on early use of long-acting injectable antipsychotics in first episode psychosis.","volume":"48","author":"Medrano","year":"2018","journal-title":"Psychopharmacol Bull"},{"issue":"8","key":"yoi200043r16","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/j.jclinepi.2013.01.012","article-title":"Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry.","volume":"66","author":"Kane","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"14","key":"yoi200043r17","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jama.2014.1030","article-title":"The imperative of overcoming barriers to the conduct of large, simple trials.","volume":"311","author":"Eapen","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"yoi200043r18","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18m12546","article-title":"Patients with early-phase schizophrenia will accept treatment with sustained-release medication (long-acting injectable antipsychotics): results from the recruitment phase of the PRELAPSE Trial.","volume":"80","author":"Kane","year":"2019","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"yoi200043r20","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/archpsyc.60.9.940","article-title":"Cost-effectiveness of supported housing for homeless persons with mental illness.","volume":"60","author":"Rosenheck","year":"2003","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"yoi200043r21","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1176\/ajp.2006.163.12.2080","article-title":"Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.","volume":"163","author":"Rosenheck","year":"2006","journal-title":"Am J Psychiatry"},{"key":"yoi200043r22","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale.","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"issue":"12","key":"yoi200043r24","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"3","key":"yoi200043r25","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","article-title":"The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome.","volume":"10","author":"Heinrichs","year":"1984","journal-title":"Schizophr Bull"},{"issue":"3","key":"yoi200043r26","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1076\/jcen.20.3.310.823","article-title":"The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity.","volume":"20","author":"Randolph","year":"1998","journal-title":"J Clin Exp Neuropsychol"},{"issue":"21","key":"yoi200043r27","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Sample size formula for proportional hazards modelling of competing risks.","volume":"23","author":"Latouche","year":"2004","journal-title":"Stat Med"},{"issue":"2","key":"yoi200043r29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/biostatistics\/4.2.207","article-title":"Waiting for organ transplantation: results of an analysis by an Institute of Medicine Committee.","volume":"4","author":"Gibbons","year":"2003","journal-title":"Biostatistics"},{"key":"yoi200043r30","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1080\/01621459.1988.10478612","article-title":"Logistic regression, survival analysis, and the Kaplan-Meier curve.","volume":"83","author":"Efron","year":"1988","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"yoi200043r32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1056\/NEJMoa002028","article-title":"A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.","volume":"346","author":"Csernansky","year":"2002","journal-title":"N Engl J Med"},{"issue":"5","key":"yoi200043r33","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/YIC.0000000000000082","article-title":"Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs.","volume":"30","author":"Bossie","year":"2015","journal-title":"Int Clin Psychopharmacol"},{"issue":"7","key":"yoi200043r34","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1001\/jamapsychiatry.2017.0624","article-title":"Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence.","volume":"74","author":"Correll","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"17","key":"yoi200043r35","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMp1002305","article-title":"Thinking outside the pillbox\u2014medication adherence as a priority for health care reform.","volume":"362","author":"Cutler","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"yoi200043r36","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1097\/00005650-200209000-00009","article-title":"Patient adherence and medical treatment outcomes: a meta-analysis.","volume":"40","author":"DiMatteo","year":"2002","journal-title":"Med Care"},{"issue":"5","key":"yoi200043r37","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication.","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"yoi200043r38","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41537-017-0039-z","article-title":"Psychosis breakthrough on antipsychotic maintenance medication (BAMM): what can we learn?","volume":"3","author":"Rubio","year":"2017","journal-title":"NPJ Schizophr"},{"key":"yoi200043r19","volume-title":"Structured Clinical Interview for DSM-IV\u00ae Axis I Disorders (SCID-I)","author":"First","year":"2012"},{"key":"yoi200043r23","first-page":"218","volume-title":"ECDEU Assessment Manual for Psychopharmacology\u2014Revised","author":"Guy","year":"1976"},{"key":"yoi200043r28","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-94-015-7983-4_14","volume-title":"Survival Analysis: State of the Art","author":"Lee","year":"1992"},{"key":"yoi200043r31","volume-title":"Longitudinal Data Analysis","author":"Hedeker","year":"2006"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2768027\/jamapsychiatry_kane_2020_oi_200043_1606923657.35759.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T19:52:20Z","timestamp":1606938740000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2768027"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.2076","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,1]]}}}